Banca de QUALIFICAÇÃO: DÉBORA FROTA COLARES

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : DÉBORA FROTA COLARES
DATE: 14/07/2025
TIME: 09:00
LOCAL: Departamento de Odontologia - SALA DE AULA 02 - Natal-RN
TITLE:

In Vitro Effects of ABT-199 on Viability, Cytotoxicity, and Apoptosis in oral Squamous Cell Lines

KEY WORDS:

Keywords: Head and neck squamous cell carcinoma. Apoptosis regulation proteins. Antineoplastic protocols. Molecular targeted therapies.

PAGES: 41
BIG AREA: Ciências da Saúde
AREA: Odontologia
SUBÁREA: Clínica Odontológica
SUMMARY:

ABSTRACT

Due to comorbidities and the long-term development of chemoresistance in the conventional treatment of head and neck squamous cell carcinoma, the search for low-toxicity alternatives has driven research into targeted therapies for this malignancy, particularly those focused on compounds capable of overcoming resistance to cell death, which is a hallmark of carcinogenesis. Among these, BH3-mimetic drugs have emerged as promising agents due to their selective action on pro-apoptotic proteins belonging to the Bcl-2 superfamily. ABT-199 (Venetoclax®), the only clinically approved drug in this class for the treatment of hematological malignancies, induces apoptosis in malignant cells through direct binding to Bcl-2, thereby inhibiting its anti-apoptotic function with a lower risk of undesirable side effects. This study aims to investigate the biological effects of ABT-199 on OTSCC cells with high Bcl-2 expression, in order to assess its antineoplastic potential and its influence on these cells. Among commercially available cell lines (SCC-9, SCC-15, SCC-25, Cal27 and HSC-3), the one exhibiting the highest Bcl-2 expression—as determined by Western blotting and RT-qPCR—will be selected for further analysis. The effects of ABT-199 will be evaluated across six experimental groups, according to the administered doses (5 μM, 10 μM, 15 μM, 20 μM, and 25 μM), either as monotherapy or in combination with 5-fluorouracil (5-FU, 50 μM), and compared to a group treated with 5-FU alone (50 μM) and a control group (PBS). Cell viability, cytotoxicity, and apoptosis assays will be performed in each group. Ultimately, the study seeks to provide evidence supporting the future clinical investigation of ABT-199 in patients with OTSCC.

COMMITTEE MEMBERS:
Presidente - 1258707 - ANTONIO DE LISBOA LOPES COSTA
Interna - 2492713 - ERICKA JANINE DANTAS DA SILVEIRA
Externo à Instituição - EVERTON FREITAS DE MORAIS - UNICAMP